Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia

Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SEVILLA · Jan 14, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating whether treating bloodstream infections caused by a bacteria called Pseudomonas aeruginosa with antibiotics for 7 days is as effective and safe as treating them for 14 days. The study aims to find out if a shorter course of antibiotics can work just as well for patients who have already been on treatment for about 6 days. It is currently recruiting participants who are adults aged 65 and older and have been diagnosed with this type of infection.

To be eligible for this trial, patients must have received active antibiotic treatment for a bloodstream infection for 6 days and be willing to sign a consent form. However, those whose infections are not well-controlled, or who have other serious infections requiring longer treatment, may not qualify. Participants can expect to be randomly assigned to either the 7-day or 14-day antibiotic treatment group and will be monitored for their health and safety throughout the study. This trial is important as it could help determine the best length of antibiotic treatment for these infections, potentially leading to more effective and shorter treatment options for patients.

Gender

ALL

Eligibility criteria

• Main inclusion criteria:
• • Adult patients with diagnosis of BSI-PA who have received 6 days (+/- 1) of active antibiotic treatment from the date of extraction of the first positive blood culture and until the moment of randomization.
• • Informed consent signed.
• Main exclusion criteria:
• • Bacteremia source not adequately controlled at least 72h before randomization.
• • Bacteremia secondary to an infection that necessarily requires prolonged antibiotic treatment more than 7 days
• • Coexistence of a different infection at the time of diagnosis of bacteremia that also requires antibiotic treatment.
• • Bacteremic pneumonia in severely immunosuppressed patients
• • Bacteremia of any origin in patients with severe neutropenia (\<500 cells / mm3) at the time of randomization.